The European Quoting Service (EQS) enables clients to meet their pre-trade pan-European transparency obligations. EQS is a quote-driven market making and trade reporting platform that supports an extensive range of Equity and Equity-like securities defined by ESMA as liquid. It does not contain securities that are already included on SETS, SETSqx or IOB because they are directly admitted by London Stock Exchange to Main Market, AIM, Professional Securities Market, International Securities Market or Admission to Trading.
Market Makers will enter non-electronically executable quotes during the Mandatory Quote Period (MQP). There will be no minimum number of market makers required per security.
The equivalent non-liquid securities are found on segment SSX4 SXEL of SETSqx.
See TRADEcho for further details.
Draper Esprit, a leading venture capital firm investing in and developing high growth digital technology businesses, today announces that it has moved its listings from London’s AIM and Dublin’s Euronext Growth Market to their respective main market partners. Its shares will today begin trading on the Premium Segment of London’s Main Market with a secondary listing on Euronext Dublin.
London Stock Exchange welcomes Zenova Group Plc to AIM in order to facilitate its plan to introduce its innovative cutting edge technologically driven products.
Zenova has developed a set of new fire safety and temperature management products that address the most pressing problems in this sector in a very efficient and cost effective way.
These comprise fire retardant pai
London, UK – 23 July 2021 – Rize UCITS ICAV (“Rize ETF”), Europe’s first specialist thematic ETF issuer, has today unveiled a brand new ETF targeting environmental sustainability. The Rize Environmental Impact 100 UCITS ETF (LIFE) is the first ETF of its kind in Europe, and is available to buy from today on London Stock Exchange trading under the tickers LIFE (USD) and LVNG (GBP). In addition t
London Stock Exchange today welcomes GENinCode plc (“GENinCode” or the “Company” with the LSE-AIM ticker “GENI”), the cardiovascular disease (“CVD”) risk assessment company focused on predictive genetics for the prevention of cardiovascular disease. The Company is incorporated in England and Wales with its UK headquarters in Oxford.
The Company has successfully raised £17 millio